| 臺大學術典藏 |
2020-05-26T09:27:29Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Hsu C;Shen Y.-C;Chih-Hsin Yang;Yeh K.-H;Lu Y.-S;Hsu C.-H;Liu H.-T;Li C.-C;Chen J.-S;Wu C.-Y;Cheng A.-L.; Hsu C; Shen Y.-C; CHIH-HSIN YANG; Yeh K.-H; Lu Y.-S; Hsu C.-H; Liu H.-T; Li C.-C; Chen J.-S; Wu C.-Y; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-26T09:27:29Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Lu Y.-S;Hsu C;Li C.-C;Kuo S.-H;Yeh K.-H;Chih-Hsin Yang;Hsu C.-H;Wu C.-Y;Cheng A.-L.; Lu Y.-S; Hsu C; Li C.-C; Kuo S.-H; Yeh K.-H; CHIH-HSIN YANG; Hsu C.-H; Wu C.-Y; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-26T09:27:28Z |
Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer
|
Yeh K.H;Lu Y.S;Hsu C.H;Lin J.F;Chao H.J;Huang T.C;Chung C.Y;Chang C.S;Chih-Hsin Yang;Cheng A.L.; Yeh K.H; Lu Y.S; Hsu C.H; Lin J.F; Chao H.J; Huang T.C; Chung C.Y; Chang C.S; CHIH-HSIN YANG; Cheng A.L. |
| 臺大學術典藏 |
2020-05-26T09:27:28Z |
Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment
|
Chih-Hsin Yang;Chen M.-C;Cheng A.-L;Hsu C.-H;Yeh K.-H;Yu Y.-C;Whang-Peng J;Yang P.-C.; CHIH-HSIN YANG; Chen M.-C; Cheng A.-L; Hsu C.-H; Yeh K.-H; Yu Y.-C; Whang-Peng J; Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:27:26Z |
Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer
|
Hsu C.-H; Cheng J.C; Wang H.-P; Lee J.-M; Yeh K.-H; CHIH-HSIN YANG; Lin J.-T; Cheng A.-L; Lee Y.-C.; Lin C.-C;Hsu C.-H;Cheng J.C;Wang H.-P;Lee J.-M;Yeh K.-H;Chih-Hsin Yang;Lin J.-T;Cheng A.-L;Lee Y.-C.; Lin C.-C |
| 臺大學術典藏 |
2020-05-26T09:27:25Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Lin C.-C;Yeh K.-H;Chih-Hsin Yang;Hsu C;Tsai Y.-C;Hsu W.-L;Cheng A.-L;Hsu C.-H.; Lin C.-C; Yeh K.-H; CHIH-HSIN YANG; Hsu C; Tsai Y.-C; Hsu W.-L; Cheng A.-L; Hsu C.-H. |
| 臺大學術典藏 |
2020-05-26T09:27:25Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C;Cheng A.-L;Hsu C.-H;Lu Y.-S;Hsu C;Yeh K.-H;Wu C.-Y;Huang C.-S;Chih-Hsin Yang; Lin C.-C; Cheng A.-L; Hsu C.-H; Lu Y.-S; Hsu C; Yeh K.-H; Wu C.-Y; Huang C.-S; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:25Z |
Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial
|
Lin C.-C; Hsu C; Hsu C.-H; Hsu W.-L; Cheng A.-L; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:21Z |
Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma
|
Chih-Hsin Yang;Cheng A.-L;Keng H.-Y;Hsu C.-H;Pu Y.-S;Lin C.-C; Lin C.-C; Pu Y.-S; Hsu C.-H; Keng H.-Y; Cheng A.-L; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:06Z |
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy
|
Chengb A.-L.;Hsu C.-H;Hong R.-L;Chih-Hsin Yang;Chang D.-Y;Shao Y.-Y;Hu F.-C;Hsu C;Lin Z.-Z; Lin Z.-Z; Hsu C; Hu F.-C; Shao Y.-Y; Chang D.-Y; CHIH-HSIN YANG; Hong R.-L; Hsu C.-H; Chengb A.-L. |
| 臺大學術典藏 |
2020-05-26T09:27:01Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
Lin Z.-Z;Shau W.-Y;Hsu C;Shao Y.-Y;Yeh Y.-C;Kuo R.N.-C;Hsu C.-H;Chih-Hsin Yang;Cheng A.-L;Lai M.-S.; Lin Z.-Z; Shau W.-Y; Hsu C; Shao Y.-Y; Yeh Y.-C; Kuo R.N.-C; Hsu C.-H; CHIH-HSIN YANG; Cheng A.-L; Lai M.-S. |
| 臺大學術典藏 |
2020-05-26T09:26:57Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C;Su W.-C;Yen C.-J;Hsu C.-H;Su W.-P;Yeh K.-H;Lu Y.-S;Cheng A.-L;Huang D.C.-L;Fritsch H;Voss F;Taube T;Chih-Hsin Yang; Lin C.-C; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; Lu Y.-S; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:16Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Lee J.-H; Chen T.W.-W; Hsu C.-H; Yen Y.-H; CHIH-HSIN YANG; Cheng A.-L; Sasaki S.-I; Chiu L.Y; Sugihara M; Ishizuka T; Oguma T; Tajima N; Lin C.-C.; Lee J.-H;Chen T.W.-W;Hsu C.-H;Yen Y.-H;Chih-Hsin Yang;Cheng A.-L;Sasaki S.-I;Chiu L.Y;Sugihara M;Ishizuka T;Oguma T;Tajima N;Lin C.-C. |
| 臺大學術典藏 |
2020-05-25T07:35:36Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Cheng A.-L; Hsu C; Yang C.-H; Lu Y.-S; Chia-Chi Lin; Bu C.-F; Yeh K.-H.; Hsu C.-H |
| 臺大學術典藏 |
2020-05-25T07:35:36Z |
A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer
|
Pu Y.-S.;Cheng A.-L;Tsai T.-C;Chen J;Hsu C.-H;Chia-Chi Lin; Chia-Chi Lin; Hsu C.-H; Chen J; Tsai T.-C; Cheng A.-L; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:34Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Chia-Chi Lin; Cheng A.-L; Hsu C.-H; Lu Y.-S; Hsu C; Yeh K.-H; Wu C.-Y; Huang C.-S; Yang C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:34Z |
Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer
|
Lee J.-M; Yeh K.-H; Yang C.-H; Lin J.-T; Cheng A.-L; Lee Y.-C.; Lee Y.-C.;Cheng A.-L;Lin J.-T;Yang C.-H;Yeh K.-H;Lee J.-M;Wang H.-P;Cheng J.C;Hsu C.-H;Chia-Chi Lin; Chia-Chi Lin; Hsu C.-H; Cheng J.C; Wang H.-P |
| 臺大學術典藏 |
2020-05-25T07:35:34Z |
Complete response of urothelial carcinoma to chemotherapy in renal allograft recipients: A two-case study
|
Pu Y.-S.;Hsu C.-H;Chia-Chi Lin; Chia-Chi Lin; Hsu C.-H; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:34Z |
Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: An effective regimen with low toxicity
|
Pu Y.-S.;Vogelzang N.J;Chen J;Cheng A.-L;Huang C.-Y;Hsu C.-H;Chia-Chi Lin; Chia-Chi Lin; Hsu C.-H; Huang C.-Y; Cheng A.-L; Chen J; Vogelzang N.J; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:33Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Chia-Chi Lin; Hsu C.-H; Huang C.-Y; Keng H.-Y; Tsai Y.-C; Huang K.-H; Cheng A.-L; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:33Z |
Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens
|
Chia-Chi Lin; Hsu C.-H; Huang C.-Y; Tsai Y.-C; Huang K.-H; Cheng A.-L; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:33Z |
Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma
|
Chia-Chi Lin; Hsu C.-H; Huang C.-Y; Cheng A.-L; Vogelzang N.J; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:32Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Yang C.-H.;Yang P.-C;Cheng A.-L;Chia-Chi Lin;Hsu C.-H;Yu C.-J;Chang Y.-C;Hsu C;Lin Z.-Z; Lin Z.-Z; Hsu C; Chang Y.-C; Yu C.-J; Hsu C.-H; Chia-Chi Lin; Cheng A.-L; Yang P.-C; Yang C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:32Z |
Systemic therapy for metastatic urothelial carcinoma
|
Chia-Chi Lin; Hsu C.-H; Pu Y.-S; Vogelzang N.J. |
| 臺大學術典藏 |
2020-05-25T07:35:32Z |
Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial
|
Chia-Chi Lin; Hsu C.-H; Hour T.-C; Cheng A.-L; Huang C.-Y; Huang K.-H; Chen J; Pu Y.-S. |
